nintedanib
Showing 51 - 75 of 81
Idiopathic Pulmonary Fibrosis, Lung Transplant; Complications Trial in Philadelphia (Nintedanib, Placebo Oral Tablet)
Unknown status
- Idiopathic Pulmonary Fibrosis
- Lung Transplant; Complications
- Nintedanib
- Placebo Oral Tablet
-
Philadelphia, PennsylvaniaTemple University Hospital
Jul 8, 2019
NSCLC Trial in Chemnitz (Microgynon, Nintedanib)
Terminated
- Carcinoma, Non-Small-Cell Lung
- Microgynon
- Nintedanib
-
Chemnitz, GermanyKlinikum Chemnitz gGmbH
Nov 22, 2018
Idiopathic Pulmonary Fibrosis Trial in United Kingdom (nintedanib, pirfenidone)
Completed
- Idiopathic Pulmonary Fibrosis
- nintedanib
- pirfenidone
-
Bristol, United Kingdom
- +8 more
Nov 5, 2018
Heathy Volunteer Trial in Daytona Beach (CC-90001, Omeprazole, Midazolam)
Completed
- Heathy Volunteer
- CC-90001
- +8 more
-
Daytona Beach, FloridaCovance Clinical Research Unit
Jan 24, 2019
Idiopathic Pulmonary Fibrosis Trial in Brazil (nintedanib)
No longer available
- Idiopathic Pulmonary Fibrosis
- nintedanib
-
Barra Mansa, Brazil
- +7 more
Feb 7, 2019
Lung Diseases, Interstitial Trial in Worldwide (Nintedanib, Placebo)
Completed
- Lung Diseases, Interstitial
- Nintedanib
- Placebo
-
Birmingham, Alabama
- +152 more
Apr 22, 2020
Colorectal Tumors Trial in Fort Wayne (Nintedanib, Capecitabine)
Terminated
- Colorectal Neoplasms
- Nintedanib
- Capecitabine
-
Fort Wayne, IndianaFort Wayne Medical Oncology Hematology
Sep 12, 2018
NSCLC Trial in Japan (Nintedanib, Docetaxel)
Completed
- Carcinoma, Non-Small-Cell Lung
- Nintedanib
- Docetaxel
-
Chiba , Kashiwa, Japan
- +5 more
Oct 4, 2018
Idiopathic Pulmonary Fibrosis Trial in Worldwide (nintedanib, )
Completed
- Idiopathic Pulmonary Fibrosis
- nintedanib
- placebo
-
Jasper, Alabama
- +85 more
Jul 16, 2019
Renal Cell Carcinoma, Colorectal Adenocarcinoma, Non-squamous NSCLC Trial in Birmingham (Nintedanib, Bevacizumab)
Completed
- Renal Cell Carcinoma
- +4 more
- Nintedanib
- Bevacizumab
-
Birmingham, AlabamaUniversity of Alabama at Birmingham Comprehensive Cancer Center
Jul 9, 2018
Scleroderma, Systemic Trial in Worldwide (Nintedanib, Placebo)
Completed
- Scleroderma, Systemic
- Nintedanib
- Placebo
-
Birmingham, Alabama
- +194 more
Nov 26, 2019
Idiopathic Pulmonary Fibrosis Trial in Worldwide (Nintedanib)
Completed
- Idiopathic Pulmonary Fibrosis
- Nintedanib
-
Jasper, Alabama
- +172 more
Feb 28, 2022
Idiopathic Pulmonary Fibrosis Trial in Worldwide (Nintedanib, Placebo, Sildenafil)
Completed
- Idiopathic Pulmonary Fibrosis
- Nintedanib
- +2 more
-
Birmingham, Alabama
- +84 more
Dec 17, 2018
Idiopathic Pulmonary Fibrosis Trial in Worldwide (Nintedanib, Pirfenidone)
Completed
- Idiopathic Pulmonary Fibrosis
- Nintedanib
- Pirfenidone
-
Danbury, Connecticut
- +22 more
Jan 17, 2018
Idiopathic Pulmonary Fibrosis Trial in Worldwide (Nintedanib, Pirfenidone)
Completed
- Idiopathic Pulmonary Fibrosis
- Nintedanib
- Pirfenidone
-
Los Angeles, California
- +37 more
May 16, 2018
Idiopathic Pulmonary Fibrosis Trial in Canada, Turkey, United States (Matching Placebo, Nintedanib)
Completed
- Idiopathic Pulmonary Fibrosis
- Matching Placebo
- Nintedanib
-
Danbury, Connecticut
- +24 more
Mar 19, 2018
Esophagogastric Adenocarcinoma, Metastatic Disease, No Previous Chemo for Metastatic Esophagogastric Cancer Trial (Nintedanib,
Withdrawn
- Esophagogastric Adenocarcinoma
- +2 more
- Nintedanib
- +4 more
- (no location specified)
May 8, 2017
Healthy Trial in Biberach (Bosentan, Nintedanib)
Completed
- Healthy
- Bosentan
- Nintedanib
-
Biberach, GermanyBoehringer Ingelheim Investigational Site
Mar 2, 2017
Idiopathic Pulmonary Fibrosis Trial in United States (nintedanib)
Approved for marketing
- Idiopathic Pulmonary Fibrosis
- nintedanib
-
Winter Park, Florida
- +6 more
May 4, 2017
Recurrent NSCLC, Squamous Cell Lung Cancer, Stage III NSCLC Trial in Buffalo, Cleveland (nintedanib)
Completed
- Recurrent Non-small Cell Lung Cancer
- +3 more
- nintedanib
-
Buffalo, New York
- +1 more
May 10, 2017
Healthy Trial in Biberach (Nintedanib)
Completed
- Healthy
- Nintedanib
-
Biberach, GermanyBoehringer Ingelheim Investigational Site
Nov 8, 2016